On March 18, 2020, President Trump signed into law the Families First Coronavirus Response Act (the “Act”) in response to the anticipated impact of COVID-19. The Act provides a broad group of employees a right to emergency paid sick leave and also expands protections under the Family and Medical Leave Act (“FMLA”). The Act also provides uninsured Americans coverage for COVID-19 testing.
Throughout our Firm’s history, Lewis Rice attorneys have made excellence the foundation of our practice. More than a century of service, since our founding in 1909 in downtown Saint Louis by Joseph Lewis and Charles Rice, gives us the experience, reputation, resources, and vision to serve our clients’ dynamic needs. We provide sophisticated legal counsel and custom-tailored solutions for the challenges facing local, regional, and national businesses.
- PublicationCoronavirus Toolkit for Employers
As of this writing, most U.S. employees face a low risk of exposure to the Coronavirus Disease 2019 (COVID-19). Nevertheless, employers are expected to act prudently in response to this significant public health event. This alert provides basic resources and simple answers to some common questions that employers may face as COVID-19 continues to spread.
- PublicationDepartment of Labor Guidance on Families First Coronavirus Response Act: Employer Takeaways
Over the past week, employers have struggled mightily to make sense of the paid leave provisions, including when they become effective, what types of leave they cover, and which employers are covered by the Act. Through a series of informal publications, most recently a Q&A published on March 24, the U.S. Department of Labor (“DOL”) has at least temporarily clarified some questions, while other answers remain elusive. This summary identifies several aspects of the Act that have generated questions and what we currently know about the answers.
- PublicationKey Points: The CARES Act – a $2.2 Trillion Coronavirus Rescue Package
On March 27, 2020, President Donald Trump signed into law the Coronavirus Aid, Relief, and Economic Security Act (“CARES Act”). The $2.2 trillion emergency economic relief package will provide assistance to American citizens, businesses, hospitals, and state and local governments who have been adversely impacted by COVID-19 through loans, grants and the creation of various tax incentives.
- PublicationNew Tax Credits under the Families First Coronavirus Response Act
On March 14, 2020, the U.S. House of Representatives passed H.R. 6201, the Families First Coronavirus Response Act (the “Act”). The House passed several technical corrections to the Act on Monday, March 16. The Senate will consider the Act this week and President Trump has indicated that he will sign it.
- PublicationThe SBA Paycheck Protection Loan Program
As discussed in our prior alert, the Senate unanimously passed bipartisan legislation titled the Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”) late on March 25, 2020. The CARES Act is “phase 3” of the U.S. government’s economic stimulus program implemented in response to the COVID-19 pandemic, and includes $2 trillion in emergency economic assistance for American citizens, businesses, hospitals, and state and local governments. While the CARES Act must pass in the House before going to President Trump for his signature, the House is currently expected to approve the CARES Act during the morning of Friday, March 27 by voice vote.
- PublicationForce Majeure and Other Contractual Considerations in the Wake of the COVID-19 Pandemic
On March 11, 2020, the World Health Organization (WHO) declared the respiratory illness called coronavirus disease 2019 (COVID-19) a pandemic, making it the first time that the WHO has declared an outbreak a pandemic since the H1N1 “swine flu” in 2009. As the COVID-19 pandemic continues its rapid, global spread and the numbers of cases and deaths rise, the commercial effects for businesses also increase, including labor issues, regulatory issues from governmental restrictions and quarantines, supply chain and logistics issues from transportation and facility disruptions, and privacy issues from the use and disclosure of medically sensitive personal information. Because these commercial effects may result in an impacted party’s inability to fully perform its obligations under its contracts, companies should consider the risks under existing contracts, as well as how to address COVID-19 and other epidemics and pandemics in future contracts.